Wells Fargo raised the firm’s price target on Globus Medical (GMED) to $79 from $66 and keeps an Overweight rating on the shares. The firm notes the company delivered impressive Q3 beat with EPS of $1.18 vs. consensus 78c. Raised 2025 targets reflect Nevro accretion earlier than expected and U.S. Spine stabilization.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $90 from $80 at Piper Sandler
- Globus Medical upgraded to Buy from Neutral at BofA
- Cautious Optimism: Hold Rating for Globus Medical Amid Strong Performance and Revenue Concerns
- Globus Medical upgraded to Buy from Hold at Truist
- Globus Medical’s Strong Q3 2025 Performance and Growth